BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 9397172)

  • 1. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
    J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
    Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
    J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
    Rewcastle GW; Palmer BD; Thompson AM; Bridges AJ; Cody DR; Zhou H; Fry DW; McMichael A; Denny WA
    J Med Chem; 1996 Apr; 39(9):1823-35. PubMed ID: 8627606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
    Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA
    J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
    J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
    J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
    Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
    Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
    J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.
    Boschelli DH; Wu Z; Klutchko SR; Showalter HD; Hamby JM; Lu GH; Major TC; Dahring TK; Batley B; Panek RL; Keiser J; Hartl BG; Kraker AJ; Klohs WD; Roberts BJ; Patmore S; Elliott WL; Steinkampf R; Bradford LA; Hallak H; Doherty AM
    J Med Chem; 1998 Oct; 41(22):4365-77. PubMed ID: 9784112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
    Klutchko SR; Zhou H; Winters RT; Tran TP; Bridges AJ; Althaus IW; Amato DM; Elliott WL; Ellis PA; Meade MA; Roberts BJ; Fry DW; Gonzales AJ; Harvey PJ; Nelson JM; Sherwood V; Han HK; Pace G; Smaill JB; Denny WA; Showalter HD
    J Med Chem; 2006 Feb; 49(4):1475-85. PubMed ID: 16480284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors.
    Sun Y; Fry DW; Vincent P; Nelson JM; Elliott W; Leopold WR
    Anticancer Res; 1999; 19(2A):919-24. PubMed ID: 10368634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.
    Bridges AJ; Zhou H; Cody DR; Rewcastle GW; McMichael A; Showalter HD; Fry DW; Kraker AJ; Denny WA
    J Med Chem; 1996 Jan; 39(1):267-76. PubMed ID: 8568816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
    Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
    Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.